Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...

The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs ...

Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many ...

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme ...

The result “pulls the rug” out from under giredestrant, according to one analyst, sparking another share selloff following disappointing obesity data last week.

The agreement ends a messy dispute that began when the telehealth firm attempted to sell a compounded form of Novo’s Wegovy pill at a cheaper price.